Mary Kathryn Dahlgren1,2, Kelly A Sagar1, Megan T Racine1, Meredith W Dreman1, Staci A Gruber1,3. 1. Cognitive and Clinical Neuroimaging Core, McLean Imaging Center, McLean Hospital, Belmont, Massachusetts. 2. Department of Psychology, Tufts University, Medford, Massachusetts. 3. Department of Psychiatry, Harvard Medical School, Boston, Massachusetts.
Abstract
OBJECTIVE: Despite growing evidence that chronic marijuana use is associated with cognitive impairment, particularly when use is initiated at an early age, national trends demonstrate significant decreases in the perceived risk of marijuana corresponding with increased use, especially among youth. The current study assessed the impact of marijuana use on executive function and whether patterns of marijuana use, including earlier age at onset, higher frequency, and increased magnitude of use, predict impairment. METHOD: Forty-four chronic, heavy marijuana smokers (37 male, 7 female) and 32 healthy, nonsmoking control participants (20 male, 12 female) recruited from the Greater Boston area completed two assessments of executive function: the Stroop Color Word Test and Wisconsin Card Sorting Test (WCST). RESULTS: Marijuana smokers had poorer executive function relative to control participants, a between-group difference that was primarily driven by individuals with early onset of marijuana use (before age 16; n = 21); significance remained even when controlling for frequency and magnitude of use. Further, earlier age at marijuana onset and increased marijuana use predicted poorer neurocognitive performance, and perseverative errors on the WCST significantly predicted marijuana group membership. CONCLUSIONS: These findings underscore the impact of early onset of marijuana use on executive function impairment independent of increased frequency and magnitude of use. In addition, poorer performance on the WCST may serve as a neuropsychological marker for heavy marijuana users. These results highlight the need for additional research to identify predictors associated with early marijuana use, as exposure to marijuana during a period of developmental vulnerability may result in negative cognitive consequences.
OBJECTIVE: Despite growing evidence that chronic marijuana use is associated with cognitive impairment, particularly when use is initiated at an early age, national trends demonstrate significant decreases in the perceived risk of marijuana corresponding with increased use, especially among youth. The current study assessed the impact of marijuana use on executive function and whether patterns of marijuana use, including earlier age at onset, higher frequency, and increased magnitude of use, predict impairment. METHOD: Forty-four chronic, heavy marijuana smokers (37 male, 7 female) and 32 healthy, nonsmoking control participants (20 male, 12 female) recruited from the Greater Boston area completed two assessments of executive function: the Stroop Color Word Test and Wisconsin Card Sorting Test (WCST). RESULTS:Marijuana smokers had poorer executive function relative to control participants, a between-group difference that was primarily driven by individuals with early onset of marijuana use (before age 16; n = 21); significance remained even when controlling for frequency and magnitude of use. Further, earlier age at marijuana onset and increased marijuana use predicted poorer neurocognitive performance, and perseverative errors on the WCST significantly predicted marijuana group membership. CONCLUSIONS: These findings underscore the impact of early onset of marijuana use on executive function impairment independent of increased frequency and magnitude of use. In addition, poorer performance on the WCST may serve as a neuropsychological marker for heavy marijuana users. These results highlight the need for additional research to identify predictors associated with early marijuana use, as exposure to marijuana during a period of developmental vulnerability may result in negative cognitive consequences.
Authors: Harrison G Pope; Amanda J Gruber; James I Hudson; Geoffrey Cohane; Marilyn A Huestis; Deborah Yurgelun-Todd Journal: Drug Alcohol Depend Date: 2003-04-01 Impact factor: 4.492
Authors: Robert A Battisti; Steven Roodenrys; Stuart J Johnstone; Nicole Pesa; Daniel F Hermens; Nadia Solowij Journal: Psychopharmacology (Berl) Date: 2010-08-19 Impact factor: 4.530
Authors: Nadia Solowij; Katy A Jones; Megan E Rozman; Sasha M Davis; Joseph Ciarrochi; Patrick C L Heaven; Dan I Lubman; Murat Yücel Journal: Psychopharmacology (Berl) Date: 2011-02-17 Impact factor: 4.530
Authors: Olivier J Barthelemy; Mark A Richardson; Timothy C Heeren; Clara A Chen; Jane M Liebschutz; Leah S Forman; Howard J Cabral; Deborah A Frank; Ruth Rose-Jacobs Journal: J Stud Alcohol Drugs Date: 2019-01 Impact factor: 2.582
Authors: Michael J Sofis; Shea M Lemley; Alan J Budney; Catherine Stanger; David P Jarmolowicz Journal: Exp Clin Psychopharmacol Date: 2019-05-09 Impact factor: 3.157
Authors: M Alejandra Infante; Tam T Nguyen-Louie; Matthew Worley; Kelly E Courtney; Clarisa Coronado; Joanna Jacobus Journal: J Int Neuropsychol Soc Date: 2019-12-11 Impact factor: 2.892
Authors: Staci A Gruber; Kelly A Sagar; Mary K Dahlgren; Megan T Racine; Rosemary T Smith; Scott E Lukas Journal: Front Pharmacol Date: 2016-10-13 Impact factor: 5.810
Authors: Reagan R Wetherill; Nathan Hager; Kanchana Jagannathan; Yasmin Mashhoon; Heather Pater; Anna Rose Childress; Teresa R Franklin Journal: Cannabis Cannabinoid Res Date: 2016-01-10
Authors: Staci A Gruber; Kelly A Sagar; Mary K Dahlgren; Atilla Gonenc; Rosemary T Smith; Ashley M Lambros; Korine B Cabrera; Scott E Lukas Journal: Front Pharmacol Date: 2018-01-17 Impact factor: 5.810